½ÃÀ庸°í¼­
»óǰÄÚµå
1392099

¼¼°è °øÈ² ¹ßÀÛ Ä¡·á ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº°, Áö¿ªº°

Global Panic Attack Treatment Market, By Drug Class, By Route of Administration, By Distribution Channel, By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è °øÈ² ¹ßÀÛ Ä¡·á ½ÃÀåÀº 2023³â 21¾ï 4,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í 2030³â¿¡´Â 63¾ï 4,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 16.8%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

º¸°í ´ë»ó ¹üÀ§ º¸°í¼­ ¼¼ºÎÁ¤º¸
±âÁسâ 2022³â 2023³â ½ÃÀå ±Ô¸ð 21¾ï 4,000¸¸ ´Þ·¯
¾÷Àû µ¥ÀÌÅÍ 2018-2021³â ¿¹Ãø ±â°£ 2023³â-2030³â
¿¹Ãø ±â°£ÀÇ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 16.80% 2030³â ½ÃÀå ±Ô¸ð ¿¹Ãø 63¾ï 4,000¸¸ ´Þ·¯
±×¸² 1. ¼¼°è °øÈ² ¹ßÀÛ Ä¡·á ½ÃÀå Á¡À¯À²(%), Áö¿ªº°, 2023³â
Global Panic Attack Treatment Market-IMG1

°øÈ² ¹ßÀÛÀº °©ÀÛ½º·± µÎ·Á¿ò°ú °í³ú¿¡ ÈÛ½ÎÀÎ °Ý·ÄÇÑ ¿¡ÇǼҵåÀ̸ç, ±×°ÍÀ» °æÇèÇÑ »ç¶÷Àº ¼è¾àÇØÁú ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀÛÀº Á¾Á¾ Ã˰¨ ¾øÀÌ ÀϾ°í, µ¿°è, È£Èí °ï¶õ, ÈäÅë µîÀÇ ½Åü Áõ»óÀ» À¯¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. °øÈ² ¹ßÀÛÀÇ Ä¡·á´Â Áõ»óÀ» ¿ÏÈ­ÇÏ°í ¹ßÀÛÀÇ ºóµµ¸¦ ÁÙÀ̰í Àü¹ÝÀûÀÎ »îÀÇ ÁúÀ» Çâ»ó½ÃŰ´Â µ¥ ÁßÁ¡À» µÓ´Ï´Ù.

½ÃÀå ¿ªÇÐ:

¼¼°è °øÈ² ¹ßÀÛ Ä¡·á ½ÃÀåÀº °¡±î¿î ¹Ì·¡¿¡ Å« ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. ¼¼°è ½ÃÀåÀÇ ¼ºÀåÀº ¼¼°è °øÈ² ¹ßÀÛÀÇ À¯º´·ü Áõ°¡¸¦ Æ÷ÇÔÇÑ ¿©·¯ ¿äÀο¡ ÀÇÇØ ÃÊ·¡µË´Ï´Ù. Á¤½Å°Ç°­¿¡ ´ëÇÑ ÀǽÄÀÌ ³ô¾ÆÁö°í °øÈ²¹ßÀÛ¿¡ ´ëÇÑ ¼ö¿ë°ú ÀÌÇØ°¡ ³ô¾ÆÁüµµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ÀÇ·á ±â¼ú°ú Ä¡·á °³ÀÔÀÇ Áøº¸·Î °øÈ² ¹ßÀÛ¿¡ ´ëÇѺ¸´Ù È¿°úÀûÀÎ Ä¡·á¹ýÀÌ °³¹ßµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹ ºÒ¾È ¹× ¿ì¿ïÁõ Çùȸ(ADAA)¿¡ µû¸£¸é, 2020³â ºÒ¾È ¹ßÀÛÀº ¹Ì±¹¿¡¼­ °¡Àå ÈçÇÑ Á¤½Å ÁúȯÀ̸ç, ¹Ì±¹¿¡¼­´Â 18¼¼ ÀÌ»óÀÇ ¼ºÀÎÀÌ ¸Å³â 4,000¸¸ ¸í °¡±îÀÌ(18.1%) ÀÌȯ ÀÖ½À´Ï´Ù. ÀÌ Ãâó¿¡ µû¸£¸é, Àü¹ÝÀû ºÒ¾È ¹ßÀÛ(GAD)Àº ¸Å³â ¼ºÀÎ 680¸¸¸í(¹Ì±¹ Àα¸ÀÇ 3.1%), °øÈ² ¹ßÀÛ(PD)Àº ¼ºÀÎ 600¸¸¸í(¹Ì±¹ Àα¸ÀÇ 2.7%)ÀÌ ¾Î°í ÀÖ½À´Ï´Ù.

±×·¯³ª ½ÃÀå ¼ºÀåÀ» ¾ïÁ¦ÇÏ´Â ¿äÀεµ ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀÇ ÁÖ¿ä °úÁ¦ Áß Çϳª´Â °øÈ² ¹ßÀÛÀ» Æ÷ÇÔÇÑ Á¤½Å °Ç°­ ¹®Á¦¿Í °ü·ÃµÈ ½ºÆ¼±×¸¶ÀÔ´Ï´Ù. ÀÌ ½ºÆ¼±×¸¶´Â Á¾Á¾ °³ÀÎÀÌ µµ¿òÀ̳ª Ä¡·á¸¦ ¿ä±¸ÇÏ´Â °ÍÀ» ¹æÇØÇÕ´Ï´Ù. °Ô´Ù°¡ °øÈ² ¹ßÀÛÀÇ Ä¡·áºñ°¡ °í¾×À̰ųª Áö¿ª¿¡ µû¶ó¼­´Â »óȯ Á¤Ã¥ÀÌ ºÒÃæºÐÇÑ °Íµµ ½ÃÀå ¼ºÀåÀÇ ÀáÀçÀûÀÎ À庮ÀÌ µÇ°í ÀÖ½À´Ï´Ù.

ÀÌ·¯ÇÑ °úÁ¦¿¡µµ ºÒ±¸ÇÏ°í ½ÃÀå¿¡´Â ¸î °¡Áö ±âȸ°¡ ÀÖ½À´Ï´Ù. °øÈ² ¹ßÀÛÀ» È¿°úÀûÀ¸·Î °ü¸®ÇÒ ¼ö ÀÖ´Â °³º°È­µÈ Ç¥Àû Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. °Ô´Ù°¡ °øÈ² ¹ßÀÛ Ä¡·áÀÇ °¡»óÇö½Ç ±â¼ú°ú ÀΰøÁö´ÉÀÇ ÅëÇÕÀº ½ÃÀå È®´ëÀÇ »õ·Î¿î ±æÀ» ¿­ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Á¦¾à ¾÷°èÀÇ ÁÖ¿ä ±â¾÷¿¡ ÀÇÇÑ R&D Ȱµ¿¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡´Â ÀÌ ½ÃÀåÀÇ ±â¼ú Çõ½ÅÀ» µÞ¹ÞħÇÏ°í ¼ºÀå ±âȸ¸¦ âÃâÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

  • º» º¸°í¼­¿¡¼­´Â 2022³âÀ» ±âÁسâÀ¸·Î ÇÑ ¿¹Ãø±â°£(2023³â-2030³â)¿¡ À־ ½ÃÀå ±Ô¸ð³ª º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) µî ¼¼°è °øÈ²¹ßÀÛÄ¡·á½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®Çß½À´Ï´Ù.
  • ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀûÀÎ ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀå¿¡ ´ëÇÑ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç°ÀÇ »ó½Ã¿Í ½ÂÀÎ, ½ÃÀ嵿Çâ°ú ÃËÁø¿äÀÎ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤¿ëÇÏ´Â °æÀï Àü·« µî¿¡ °üÇÑ Áß¿äÇÑ °íÂûÀ» Á¦°øÇÕ´Ï´Ù.
  • GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Bristol-Myers Squibb Company, AstraZeneca, Pfizer Inc., Johnson & Johnson Services, Inc., Bausch Health Companies Inc., H Lundbeck A/S µî ¼¼°è °øÈ² ¹ßÀÛ Ä¡·á ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ±â¾÷ÀÇ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ½ÇÀû, Àü·«¿¡ µû¶ó ÇÁ·ÎÆÄÀÏÇϰí ÀÖ½À´Ï´Ù.
  • ÀÌ º¸°í¼­¿¡¼­ ÀλçÀÌÆ®À» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, ±â¼ú ¾÷±×·¹À̵å, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
  • ¼¼°è °øÈ² ¹ßÀÛ Ä¡·á ½ÃÀå º¸°í¼­´Â ¾÷°è ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü°¡ÀÚ, À繫 ºÐ¼®°¡ µî ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚ´Â ¼¼°è °øÈ² ¹ßÀÛ Ä¡·á ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º·ÎºÎÅÍ ÀÌÀÍÀ» ¾òÀ» ¼ö ÀÖÀ¸¸ç ÀÇ»ç °áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦

  • Á¶»ç ¸ñÀû
  • °¡Á¤
  • ¾à¾î

Á¦2Àå ½ÃÀå Àü¸Á

  • º¸°í¼­ ¼³¸í
    • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä ¿ä¾à
  • Coherent Opportunity Map(COM)

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
  • ºÒ¾ÈÁõ°ú °øÈ² ¹ßÀÛÀÇ À¯º´·ü Áõ°¡
    • ¾ïÁ¦¿äÀÎ
  • ¾àÀÇ ºÎÀÛ¿ë°ú ¾ÈÀü¼ºÀÇ ¹®Á¦
    • ±âȸ
  • ¿ø°ÝÀÇ·á¿Í ÀüÀÚ¿ä¹ýÀÇ ÀÌ¿ëÀÌ È®´ë
  • ¿µÇ⠺м®
  • ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • Á¦Ç° Ãâ½Ã/½ÂÀÎ
  • PEST ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • ÇÕº´°ú Àμö ½Ã³ª¸®¿À

Á¦4Àå ¼¼°è °øÈ² ¹ßÀÛ Ä¡·á ½ÃÀå - Äڷγª ¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

  • ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°Áõ(COVID-19)ÀÇ ¿ªÇÐ
  • °ø±ÞÃø°ú ¼ö¿äÃø ºÐ¼®
  • °æÁ¦Àû ¿µÇâ

Á¦5Àå ¼¼°è °øÈ² ¹ßÀÛ Ä¡·á ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°(2018³â-2030³â)

  • ¼Ò°³
  • Ç׿ì¿ïÁ¦
  • Ç׺ҾÈÁ¦
  • CGRP ±æÇ×Á¦
  • ±âŸ

Á¦6Àå ¼¼°è °øÈ² ¹ßÀÛ Ä¡·á ½ÃÀå : Åõ¿© °æ·Îº°(2018³â-2030³â)

  • ¼Ò°³
  • °æ±¸
  • Á¤¸Æ³»
  • ±ÙÀ°³»
  • ¼³ÇÏ
  • ±âŸ

Á¦7Àå ¼¼°è °øÈ² ¹ßÀÛ Ä¡·á ½ÃÀå : À¯Åë ä³Îº°(2018³â-2030³â)

  • ¼Ò°³
  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹

Á¦8Àå ¼¼°è °øÈ² ¹ßÀÛ Ä¡·á ½ÃÀå : Áö¿ªº°(2018³â-2030³â)

  • ¼Ò°³
  • ºÏ¹Ì
  • ¹Ì±¹
  • ij³ª´Ù
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • ºê¶óÁú
  • ¾Æ¸£ÇîÆ¼³ª
  • ¸ß½ÃÄÚ
  • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • À¯·´
  • µ¶ÀÏ
  • ¿µ±¹
  • ½ºÆäÀÎ
  • ÇÁ¶û½º
  • ÀÌÅ»¸®¾Æ
  • ·¯½Ã¾Æ
  • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áß±¹
  • Àεµ
  • ÀϺ»
  • È£ÁÖ
  • Çѱ¹
  • ASEAN ±¹°¡
  • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿
  • GCC ±¹°¡
  • À̽º¶ó¿¤
  • ±âŸ Áßµ¿
  • ¾ÆÇÁ¸®Ä«
  • ³²¾ÆÇÁ¸®Ä«
  • ºÏ¾ÆÇÁ¸®Ä«
  • Áß¾Ó ¾ÆÇÁ¸®Ä«

Á¦9Àå °æÀï ±¸µµ

  • GlaxoSmithKline plc.
  • Hoffmann-La Roche Ltd
  • Teva Pharmaceutical Industries Ltd.
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • AstraZeneca
  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • Bausch Health Companies Inc.
  • Lundbeck A/S

Á¦10Àå ¼½¼Ç

  • Á¶»ç ¹æ¹ý
  • ÃâÆÇ»ç¿¡ ´ëÇØ
BJH 23.12.21

Global Panic Attack Treatment Market is expected to reach US$ 6.34 Bn by 2030, from US$ 2.14 Bn in 2023, exhibiting a CAGR of 16.8% during the forecast period.

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 2.14 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 16.80% 2030 Value Projection: US$ 6.34 Bn
Figure 1. Global Panic Attack Treatment Market Share (%), By Region, 2023
Global Panic Attack Treatment Market - IMG1

Panic attacks are intense episodes of sudden fear or distress that can be debilitating for individuals who experience them. These attacks often come without warning, and can cause physical symptoms such as heart palpitations, shortness of breath, and chest pain. Panic attack treatment focuses on relieving symptoms, reducing the frequency of attacks, and improving overall quality of life.

Market Dynamics:

Global panic attack treatment market is expected to witness significant growth in the near future. The global market growth is driven by several factors including the increasing prevalence of panic disorders worldwide. Rising awareness about mental health, coupled with the growing acceptance and understanding of panic attacks, are also contributing to market growth. Advancements in medical technology and therapeutic interventions have led to the development of more effective treatments for panic attacks. For instance, according to the Anxiety and Depression Association of America (ADAA), in 2020, anxiety disorders are the most common mental illness in the U.S. that affects nearly 40 million adults (18.1%) in the U.S. aged 18 years and older, every year. According to the same source, generalized anxiety disorder (GAD) affects 6.8 million adults, or 3.1% of the U.S. population and panic disorder (PD) affects 6 million adults, or 2.7% of the U.S. population, each year.

However, there are certain factors that may restrain the market growth. One of the key challenges in this market is the stigma associated with mental health issues including panic attacks. This stigma often prevents individuals from seeking help and treatment. Moreover, the high cost of panic attack treatments and a lack of reimbursement policies in some regions are also potential barriers to the market growth.

Despite these challenges, several opportunities exist in the market. There is a growing demand for personalized and targeted therapies that can effectively manage panic attacks. Moreover, the integration of virtual reality technology and artificial intelligence in panic attack treatment is expected to open new avenues for market expansion. Increasing investments in research and development activities by key players in the pharmaceutical industry are likely to boost innovation in this market and create growth opportunities.

Key Features of the Study:

  • This report provides in-depth analysis of the global panic attack treatment market, including market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period (2023-2030), with 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • Key players in the global panic attack treatment market likeGlaxoSmithKline plc., F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Bristol-Myers Squibb Company, AstraZeneca, Pfizer Inc., Johnson & Johnson Services, Inc., Bausch Health Companies Inc., and H. Lundbeck A/S are profiled based on company highlights, product portfolios, key highlights, financial performance, and strategies
  • Insights from this report would allow marketers and management authorities to make informed decisions regarding future product launches, technology upgrades, market expansion, and marketing tactics
  • The global panic attack treatment market report caters to various stakeholders, including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts in the industry
  • Stakeholders can benefit from various strategy matrices used in analyzing the global panic attack treatment market, which would facilitate ease in decision-making

Detailed Segmentation:

  • By Drug Class
    • Antidepressants
    • Anti-anxiety Drugs
    • CGRP Antagonists
    • Others
  • By Route of Administration
    • Oral
    • Intravenous
    • Intramuscular
    • Sublingual
    • Others
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East
    • Africa
  • Top companies in Global Panic Attack Treatment Market:
    • GlaxoSmithKline plc.
    • F.Hoffmann-La Roche Ltd
    • Teva Pharmaceutical Industries Ltd.
    • Eli Lilly and Company
    • Bristol-Myers Squibb Company
    • AstraZeneca
    • Pfizer Inc.
    • Johnson & Johnson Services, Inc.
    • Bausch Health Companies Inc.
    • Lundbeck A/S

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Class
    • Market Snippet, By Route of Administration
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
  • Increasing prevalence of anxiety and panic disorders
    • Restraints
  • Side effects and safety issues with medications
    • Opportunities
  • Growing use of telemedicine and e-therapies
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Panic Attack Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Panic Attack Treatment Market, By Drug Class, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019 - 2030
    • Segment Trends
  • Antidepressants
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Anti-anxiety Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • CGRP Antagonists
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

6. Global Panic Attack Treatment Market, By Route of Administration, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019- 2030
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Intravenous
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Intramuscular
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Sublingual
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

7. Global Panic Attack Treatment Market, By Distribution Channel, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2019- 2030
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

8. Global Panic Attack Treatment Market, By Region, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Region, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Region, 2019-2030
    • Country Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030,( US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2018-2030, (US$ Bn)
  • South Africa
  • North Africa
  • Central Africa

9. Competitive Landscape

  • GlaxoSmithKline plc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Hoffmann-La Roche Ltd
  • Teva Pharmaceutical Industries Ltd.
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • AstraZeneca
  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • Bausch Health Companies Inc.
  • Lundbeck A/S
  • Analyst Views

10. Section

  • Research Methodology
  • About us
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦